Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights

Table 1 Assessment of colon lesions in rats subjected to obstruction of the left colic artery and vein by two ligations for 15 min (pale flat areas without mucosal folds as a percentage of the area of the blood-deprived colon segment; mean ± SD)

Medication (/kg, 1-ml bath/rat) at the 25-mm blood-flow-deprived colon segment	Pale areas without mucosal folds as a percentage of the area of the blood-deprived colon segment, mean ± SD
0.9% NaCl (control)	46 ± 8
BPC 157 (10 µg)	7 ± 2a
L-NAME (5 mg)	80 ± 10a
L-arginine (100 mg)	65 ± 6a
L-NAME (5 mg) + L-arginine (100 mg)	50 ± 8
L-NAME (5 mg) + BPC 157 (10 µg)	10 ± 4a
L-arginine (100 mg) + BPC 157 (10 µg)	6 ± 2a
L-NAME (5 mg) + L-arginine (100 mg) + BPC 157 (10 µg)	8 ± 2a

The following medications or treatments (/kg, 1-mL bath/rat) were applied to the 25-mm blood-flow-deprived colon segment at 1 min post-injury: BPC 157 (10 µg); the NOS blocker L-NAME (5 mg) and the NOS substrate L-arginine (100 mg), alone or combined; equal volume of saline bath (controls).

^aP < 0.05 at least vs control.